Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen (AMGN) ended the recent trading session at $277.88, demonstrating a +1.62% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.53 ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during ...

Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $272.11 which represents a slight increase of $2.68 or 0.99% from the prior close of $269.43. The stock opened at $276.97 and touched a ...

Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It ...

Eight of the 30 Dow components lost value in 2024. Here's a quick look at each company, to help you determine which dividend ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...